Abstract: The invention provides a vaccine for protecting a human patient against infection by a human influenza virus strain, wherein the vaccine comprises an antigen from an avian influenza virus strain that can cause highly pathogenic avian influenza. The antigen can invoke an antibody response in the patient that is capable of neutralising said human influenza virus strain. Whereas the prior art used known non-pathogenic avian strains to generate antibodies in humans against known pathogenic avian strains, the invention uses known pathogenic avian strains to protect against emerging pathogenic human strains. Furthermore, whereas the prior art focused on achieving a close antigenic match between the vaccine strain and the target strain, the invention selects vaccine strains based on their pathogenicity, regardless of any perceived close antigenic relationship to the target strain.

Abstract: The present invention relates to compounds that are useful for treating cellular proliferative diseases, for treating disorders mediated, at least in part, by KSP, and for inhibiting KSP. The invention also related to pharmaceutical compositions comprising such compounds, methods of treating cancer by the administration of such compositions, and processes for the preparation of the compounds. Compounds of the invention have the following formula: formula (I).

Abstract: Compounds having formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and combinations with other agents. A method of treating a patient comprises administering a pharmaceutical formulation according to the invention to a patient in need thereof.

Abstract: A machine tool is provided with at least one tool spindle which is travelling in a work space (11) and on which a tool receptacle for clamping tools is provided. The machine tool also contains a magazine for tools which can be introduced into the tool receptacle in the tool spindle, the magazine having a transport chain which can be moved back and forth in a transport direction and on which carriers are arranged for receiving tools. The carriers extend from the transport chain essentially transversely to the transport direction. At least one carrier has at least two storage spaces for tools.

Abstract: The invention provides compositions and kits comprising: (a) a saccharide antigen conjugated to a carrier; and (b) an alpha-glycosylceramide adjuvant. The invention further provides uses of the compositions. It has been found that suppression of anti-saccharide immune responses by alpha-glycosylceramides can be reversed by conjugating the saccharide to a carrier.

Abstract: A highly concentrated, low salt-containing, biologically active syrup form of IGF-I or variant thereof and methods for its preparation are provided. This novel syrup form of IGF-I has an IGF-I concentration of at least about 250 mg/ml, a density of about 1.0 g/ml to about 1.2 g/ml, and a viscosity of about 13,000 centipoise (cps) to about 19,000 cps, as measured at ambient temperature (23° C.). The IGF-I syrup is prepared by precipitating or partitioning IGF-I from solution, preferably by adjusting the solution pH or by use of a solubility enhancer to concentrate IGF-I in solution followed by removal of the solubility enhancer. The precipitated syrup is useful as a means of storing IGF-I in a stable form and as a means of preparing compositions comprising biologically active IGF-I. Pharmaceutical compositions and kits comprising this concentrated IGF-I syrup are provided.

Abstract: N. gonorrhoeae is a bacterial pathogen which causes diseases including gonorrhoea, urethritis, cervicitis and pelvic inflammatory disease. In addition, like other inflammatory SYDs, infection is believed to enhance HIV transmission. Within the many proteins of the gonococcal *enome, six have been found to be particularly suitable for immunisation purposes, particularly', when used in combinations. The invention therefore provides a composition comprising two or more of the following antigens: (1) OmpA; (2) OmpH; (3) PPIase; (4) ngs41; (5) ngsl 17; and (6)', App.

Abstract: A method for preparing a protein-saccharide conjugate, comprising the steps of: (a) preparing an aqueous growth medium comprising soy peptone as a nitrogen source; (b) inoculating the medium with a Neisseria meningitidis bacterium; (c) incubating the medium to allow growth of the bacterium; (d) preparing capsular saccharide from the bacterium; and (e) conjugating the capsular saccharide to a carrier protein, to give the protein-saccharide conjugate is disclosed. The conjugates are useful in vaccine production.

Abstract: To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of Neisseria, particularly N. meningitidis and N. gonorrhoeae.

Abstract: A variety of small molecule, guanidine-containing molecules capable of acting as MC4-R agonists are provided. The compounds are useful in treating MC4-R mediated diseases when administered to subjects. The compounds have the formula IA and IB.

Abstract: The invention provides a method of treating or preventing a pathologic state in a mammal. The method comprises administering to the mammal a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system. The promoter of T-cell expansion and inducer of CD40 stimulation are administered in synergistically effective amounts to treat or prevent the pathologic state in the mammal. The invention also provides a method of assessing the effectiveness of treatment of a pathologic state in a mammal, wherein the mammal has been administered a promoter of T-cell expansion and an inducer of CD40 stimulation, wherein CD40 is stimulated on cells of the immune system.

Abstract: Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.

Abstract: The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3? and GSK3? polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

Abstract: A machine tool has a work space (17) in which a device (15) for accommodating workpieces (16) to be machined is arranged. The machine tool further has a work spindle (18) for machining the workpieces (16) and a slide (34) which carries the work spindle (18) and is traversable in a longitudinal direction relative to the device (15), a respective cover (25), variable in length in the longitudinal direction (x), for the work space (17) being provided on the slide (34) on each of its sides, said cover (25) being connected with its respective first end to the slide (34) and with its respective second end to a side wall (21, 22; 51) of the work space (17). Each cover (25) variable in length has a respective rear wall (26) and a respective top (27), whereby the top (27) is connected to the rear wall (26) in a detachable, push-in, manner. A further flexible cover (31) is arranged in front of the slide (34) to protect the work space (17) at the bottom.

Abstract: In the case of a machine tool which comprises at least one working spindle with a tool-holding fixture for tool holders carrying tools, and a tool changer with a gripper for the tool holders in order to transfer the tool holders between their magazine position, which is spaced apart from the tool-holding fixture, and their working position in the tool-holding fixture, a clamping system with a clamping apparatus by means of which a tool holder inserted into the tool-holding fixture is fixed is arranged in the working spindle, the clamping system additionally comprising a retaining apparatus for a tool holder situated in the tool-holding fixture. In the case of a method carried out on this machine tool, the clamping system carries out a retaining operation which temporally precedes the clamping operation in order to grasp the tool holder inserted into the tool-holding fixture before the clamping apparatus fixes the tool holder.

Abstract: Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Abstract: Heteroaryl-fused pyrimidinyl compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the heteroaryl-fused pyrimidinyl compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Abstract: Methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40 expressing cells, such as B cells.

Abstract: The present invention is directed to the purification and commercialization of therapeutic polypeptides that have. In one aspect of the invention, a method of purifying Interferon ?-1b using size exclusion chromatography is provided. In another aspect of the invention, a method of purifying a polypeptide using size chromatography is provided. A third aspect provides a method of commercializing a polypeptide.